Jin-Xian Huang (Jin Xian Huang, Jinxian Huang)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 19

Top Venues

International journal of rheumatic diseases

Arthritis & rheumatology (Hoboken, N.J.)

Annals of the rheumatic diseases

Disease markers

The University of Hong Kong-Shenzhen Hospital

Third Affiliated Hospital of Sun Yat-Sen University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The University of Hong Kong-Shenzhen Hospital Oct 08 2013

China

Associate Chief Physician :: Rheumatology

The University of Hong Kong-Shenzhen Hospital Oct 08 2013

China

Associate Chief Physician :: Rheumatology

The Fourth People's Hospital of Shenzhen Jul 01 2010 - Oct 01 2013

China

Resident, Attending physician :: Rheumatology

Education History

Third Affiliated Hospital of Sun Yat-Sen University Sep 01 2005 - Jun 21 2010

China

PHD :: Rheumatology

Sun Yat-Sen University Sep 01 2000 - Jul 01 2005

China

BSC :: Clinical Medicine

Publications

Zhong-Chao Fu, Xiao-Gui Cheng, Guo-Wen Zhang, Ran-Geng Shi, Li-Jun Zhang, Hai-Tian Sun, Jin-Xian Huang
Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China. International journal of rheumatic diseases 27 (5) (2024)
Lin Wen, Yan-Xia Chen, Jun-Ru Liu, Tao Li, Jin-Zhao Jiang, Jia-Qi Guo, Li-Jun Zhang, Jin-Xian Huang
Case report: Inflammatory bowel disease triggered by secukinumab in a female case of axial spondyloarthritis accompanied with symptomatic epilepsy. International journal of rheumatic diseases 27 (5) (2024)
Zhong-Chao Fu, Xiao-Gui Cheng, Guo-Wen Zhang, Ran-Geng Shi, Li-Jun Zhang, Hai-Tian Sun, Jin-Xian Huang
Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China. International journal of rheumatic diseases 27 (5) (2024)
Lin Wen, Yan-Xia Chen, Jun-Ru Liu, Tao Li, Jin-Zhao Jiang, Jia-Qi Guo, Li-Jun Zhang, Jin-Xian Huang
Case report: Inflammatory bowel disease triggered by secukinumab in a female case of axial spondyloarthritis accompanied with symptomatic epilepsy. International journal of rheumatic diseases 27 (5) (2024)
Jin-Xian Huang, Guo-Wen Zhang
Long-term follow-up of immunogenicity in radiographic axial spondyloarthritis patients: beyond drug survival and tapering. Comment on the article by Clarissa et al. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Jin-Xian Huang, Guo-Wen Zhang
Long-term follow-up of anti-infliximab antibodies in radiographic axial spondyloarthritis patients: a marker of drug survival and tapering: comment on the article by Clarissa et al. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Jin-Xian Huang, Yung-Heng Lee, Pui-Ying Leong, James Cheng-Chung Wei
Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis. International journal of rheumatic diseases 27 (1) (2023)
Jin-Xian Huang, Yung-Heng Lee, Meng-Yu Ko, James Cheng-Chung Wei
Calprotectin in psoriatic arthritis: Inflammation and beyond. International journal of rheumatic diseases 26 (1) (2023)
Jin-Xian Huang, Yung-Heng Lee, Pui-Ying Leong, James Cheng-Chung Wei
Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis. International journal of rheumatic diseases (2023)
Jin-Xian Huang, Yung-Heng Lee, Meng-Yu Ko, James Cheng-Chung Wei
Calprotectin in psoriatic arthritis: Inflammation and beyond. International journal of rheumatic diseases 26 (1) (2023)
Jin-Xian Huang, James Cheng-Chung Wei
Janus kinase inhibitors: a future all-rounder in axial spondyloarthritis? Immunotherapy (2023)
Jin-Xian Huang, Yung-Heng Lee, James Cheng-Chung Wei
Optimal composite measures for psoriatic arthritis. International journal of rheumatic diseases 26 (10) (2023)
Jin-Xian Huang, Yung-Heng Lee, Pui-Ying Leong, James Cheng-Chung Wei
Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis. International journal of rheumatic diseases 27 (1) (2023)
Jin-Xian Huang, James Cheng Chung Wei
Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis? American journal of respiratory and critical care medicine 206 (7) (2022)
Jin-Xian Huang, Li-Jun Zhang, James Cheng-Chung Wei
Interleukin-17 inhibitor, is it safer than tumor necrosis factor inhibitor? International journal of rheumatic diseases 24 (7) (2021)
Yan Zhao, Jin-Xian Huang
Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial'. Annals of the rheumatic diseases (2021)
Jin-Xian Huang, Pui-Ying Leong, James Cheng Chung Wei
Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli et al. Annals of the rheumatic diseases (2020)
Jin-Xian Huang, Li-Jun Zhang
Successful treatment of tofacitinib in a case with rheumatoid arthritis who experienced hepatitis B virus reactivation induced by tocilizumab and recovered from entecavir rescue therapy. Archives of rheumatology 36 (3) (2020)
Jin-Xian Huang, Zhihua Yin, Guoxiang Song, Shengjin Cui, Jinzhao Jiang, Lijun Zhang
Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis. Disease markers 2017 (2017)

Jin-Xian Huang.css-eqlu8i{font-size:small;padding-left:4px;} (Jin Xian Huang, Jinxian Huang)

Publication Activity (10 Years)

Top Topics

Top Venues

Jin-Xian Huang (Jin Xian Huang, Jinxian Huang)